Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25042
Title: Cost-Effectiveness of Treatment of Women Aged 70 Years and Older with Both Osteopenia and Microstructural Deterioration.
Austin Authors: Liew, Danny;Chapurlat, R D;Sornay-Rendu, E;Lespessailles, Eric;Peng, Yu;Seeman, Ego 
Affiliation: Dept Social and Preventative medicine, Alfred Hospital, Monash University, Melbourne, Australia
INSERM UMR 1033, Université de Lyon, Lyon 69437, France
Straxcorp, 410 Collins st, Melbourne, Australia
IPROS, Université d'Orléans, Orléans, France
Endocrinology
Medicine (University of Melbourne)
Issue Date: Jan-2021
metadata.dc.date: 2020-10-09
Publication information: Bone 2021; 142: 115682
Abstract: Treatment is usually withheld from women with osteopenia even though they are the source of over 70% of all women having fragility fractures. As microstructural deterioration increases fracture risk and zoledronate reduces it, we aimed to determine whether identifying and treating women with osteopenia and severe microstructural deterioration is cost-effective. We also compared the health economic outcomes of 'global' versus 'targeted' treatment using SFS of women aged ≥70 years with osteopenia. We assessed the cost-effectiveness from using a Markov model that simulated 10-year follow up of women with osteopenia. Decision analysis compared measurement of distal radial microstructure using high resolution peripheral computed tomography (at a cost of USD $210) to target women with severe microstructural deterioration for zoledronate treatment, compared to standard care defined as measurement of bone mineral density with treatment recommended when femoral neck BMD T score is ≤ -2.5 SD with or without a prevalent fracture. In the 'global' treatment approach, high resolution peripheral quantitative tomography (HRpQCT) was not undertaken. US healthcare system. A hypothetical cohort of 1000 women aged ≥70 years with osteopenia and no previous fractures was studied. Measures Fractures, deaths, years of life lived, quality-adjusted life years (QALYs) lived and costs. Data inputs were obtained from published sources. A 3% annual discount rate was applied to future health benefits and costs. Women in the standard care group incurred 327 fractures during 7341.0 years and 4914.2 QALYs lived. Women in the intervention group incurred 300 fractures (number needed to treat 37) during 7359.2 years and 4928.8 QALYs lived. Net costs were USD $4,862,669 and $4,952,004, respectively, equating to 18.1 years of life saved and 14.6 QALYs saved, and incremental cost-effectiveness ratios of $4992 per year of life saved and $6135 per QALY saved. These ratios are well within the threshold considered to be cost-effective. Sensitivity analyses indicated the results were robust. Relative to standard of care, 'global' and 'targeted' treatment respectively resulted in 0.0364 vs. 0.0181 years of life (YoLS) saved per person, and 0.0292 and 0.0146 QALYs saved per person. The net costs per person for the respective approaches were $US 359 and $US 89. The incremental cost-effectiveness ratios were $9,864 per YoLS and $12,290 per QALY saved for the 'global' approach and $4,992 per YoLS and $6,135 per QALY saved for the 'targeted' approach. Identifying and treating women ≥70 years of age with osteopenia and microstructural deterioration with zoledronate cost-effectively reduces the morbidity and mortality imposed by fragility fractures. This 'targeted' approach is more cost-effective than a 'global' approach and incurs only 25% of total costs. Implication Women with osteopenia with bone fragility due to microstructural deterioration should be identified and targeted for treatment.
URI: https://ahro.austin.org.au/austinjspui/handle/1/25042
DOI: 10.1016/j.bone.2020.115682
PubMed URL: 33039577
Type: Journal Article
Subjects: bone mineral density
cost effectiveness
microstructural deterioration
osteopenia
osteoporosis
screening
treatment
Appears in Collections:Journal articles

Show full item record

Page view(s)

22
checked on Nov 30, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.